Drug Profile

JCXH 211

Alternative Names: JCXH-211

Latest Information Update: 21 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Immorna
Class Antineoplastics; Immunotherapies; RNA
Mechanism of Action Interleukin-12 expression stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Solid tumours
Phase I Glioblastoma

Most Recent Events

21 Jan 2025 Immorna Biotherapeutics plans a phase I trial for Solid tumours (Metastatic disease, Combination therapy, Second line therapy or greater) (Intratumoural, Injection) in February 2025 (NCT06781125)
08 Jul 2024 US FDA approves IND application for JCXH 211 in Solid tumours
08 Jul 2024 Immorna Biotherapeutics plans a phase I/II trial in Solid tumours (Monotherapy, Combination therapy, Late-stage disease) in USA (IV)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com